ClinicalTrials.gg
RecruitingNCT05369052Updated Oct 13, 2026

Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)

A Phase 3 interventional study of contezolid acefosamil (IV)/contezolid (PO) and Linezolid (IV and PO) in Diabetic Foot Infection, sponsored by MicuRx. Recruiting at 14 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by MicuRx · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.
Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
865
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects with moderate or severe DFI.

Read the detailed description

Approximately 865 subjects (519 contezolid acefosamil/contezolid: 346 linezolid) will be enrolled with moderate or severe DFI that are confirmed or suspected to be due to a Gram-positive bacterial pathogen (MITT analysis set).

02

Conditions studied

  • Diabetic Foot Infection

Browse trials for

03

In context

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

This study's planned enrollment of 865 is above the median of 60 across 849 interventional studies indexed under Diabetic Foot.

Browse Diabetic Foot studies →

Lead sponsor

MicuRx is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have diabetes mellitus (type 1 or 2) per the American Diabetes Association criteria
  • Have a foot infection that started at or below the malleolus and does not extend above the knee
  • Foot infection that meets the IWGDF DFI criteria for classification 3 (moderate infection) or 4 (severe infection)
  • Foot infection had acute onset or worsening of signs and symptoms within the past 14 days

Exclusion criteria

Exclusion Criteria:

  • Previous DFI known or suspected to be caused by Gram-positive pathogens that are resistant to oxazolidinone antibiotics
  • DFI with presumptive evidence or suspicion of osteomyelitis
  • Necrotizing fasciitis, crepitant cellulitis, wet gangrene, gas gangrene, ecthyma gangrenosum, septic arthritis, or severely impaired arterial supply to any portion of the affected foot which may need revascularization before the end of the study
  • Evidence of significant hepatic, renal, hematologic, or immunologic disease
  • Females who are pregnant or breastfeeding
  • Prior receipt of any formulation of contezolid acefosamil or contezolid
  • Inability to cooperate fully with the requirements of the study protocol, including the schedule of events, or likely to be noncompliant with any study requirements, or the Investigator determines that the subject should not participate in the study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
865 participants (estimated)

Study arms

  • Experimental
    contezolid acefosamil/contezolid

    Drug: contezolid acefosamil (IV)/contezolid (PO)

  • Active comparator
    linezolid

    Drug: Linezolid (IV and PO)

Interventions

  • Drugcontezolid acefosamil (IV)/contezolid (PO)

    Drug page: ContezolidStudies of ContezolidContezolid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)

  • DrugLinezolid (IV and PO)

    Drug page: LinezolidStudies of LinezolidLinezolid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)

06

What researchers measure

Primary outcomes

  1. Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators

    The primary objective is to evaluate the Investigator's assessment of clinical response at the D35 visit in subjects receiving contezolid acefosamil/contezolid compared to subjects receiving linezolid in the MITT analysis

    Time frame: Day 35

  2. Adverse events - symptoms reported by subjects

    Evaluate safety of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO)

    Time frame: 28-35 days after End-of-Therapy (EOT)

  3. Clinical laboratory assessment - complete blood count

    Will be evaluated under safety of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO)

    Time frame: 28-35 days after End-of-Therapy (EOT)

  4. Vital signs - heart rate

    Will be evaluated under safety of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO)

    Time frame: 28-35 days after End-of-Therapy (EOT)

Secondary outcomes

  1. Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators

    Evaluate the Investigator's assessment of clinical response at EOT visit in the MITT analysis set

    Time frame: 14-28 days

  2. Clinical response calculated with percentage of subjects with resolution of DFI signs and symptoms and requiring no further therapy as assessed by Investigators

    Evaluate the Investigator's assessment of clinical response at Day 10 (D10) and Late Follow-Up visits (LFU; 28-35 days after EOT) in the MITT analysis set

    Time frame: Day 10, 28-35 days after EOT

07

Study locations

14 of 14 sites recruiting
  • New Hope Research Development
    Corona, California 92882, United States
    Recruiting
  • ILD Research Center
    Vista, California 92081, United States
    Recruiting
  • MHAT Sveti Nikolay Chudotvorets EOOD
    Lom, Bulgaria
    Recruiting
  • Multiprofile Hospital for Active Treatment - KANEV
    Rousse, Bulgaria
    Recruiting
  • Medical Institute Ministry of Interior Central Clinical Base
    Sofia, Bulgaria
    Recruiting
  • University Multidisciplinary Hospital for Active Treatment and Emergency Medicine 'N. I. Priogov´
    Sofia, Bulgaria
    Recruiting
  • South-Estonian Hospital Ltd.
    Võru, Estonia
    Recruiting
  • LTD High Technology Hospital Med Center
    Batumi, Georgia
    Recruiting
  • JSC Vian - West Georgia Medical Center
    Kutaisi, Georgia
    Recruiting
  • GMV Care& Research - Maria Cecilia Hospital
    Cotignola, Italy
    Recruiting
  • Daugavpils Regional Hospital
    Daugavpils, Latvia
    Recruiting
  • Instytut Medycyny Wsi im. W. Chodzki
    Lublin, Poland
    Recruiting
  • PODEMA Sp. z o.o.
    Warsaw, Poland
    Recruiting
  • University Clinical Center Kragujevac
    Kragujevac, Serbia
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Jun 2027, 61 months after the start.

Of 18 phase 3 interventional studies under Diabetic Foot, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 61 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2022
First posted
May 11, 2022
StartActual
May 3, 2022
Primary completionEst.
Jun 30, 2027was Jun 2026
CompletionEst.
Jun 30, 2027was Jun 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→Jun 30, 2027
Oct 13, 2026
Study completion
Jun 30, 2026→Jun 30, 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Jun 30, 2026→Jun 30, 2027
    Study completion Jun 30, 2026→Jun 30, 2027
    + 3 other changes: verification date, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05369052
Lead sponsor
MicuRx
Responsible party
Sponsor
First posted
May 11, 2022
Start date
May 3, 2022
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Clinical coordinator
Contact
info@micurx.com
510-782-2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Contezolid

Start the discussion